Loading...

Edward Ball

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0960
La Jolla CA 92093
Phone858-822-6600
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    Dr. Ball’s research focuses on the development of monoclonal antibody (mAb)-targeted immunotherapy and its translation to the treatment of patients with malignancy. His lab produced mAbs to myeloid-associated antigens expressed on myeloid leukemia cells. These antibodies have been used clinically for the diagnosis and treatment of acute myeloid leukemia (AML).He has conducted multi-center clinical trials using antibody-mediated purging using the AML cells from the marrow of patients with leukemia prior to transplantation, after high dose chemotherapy. He has also developed in vivo therapeutics using an anti-CD15 mAb and a bispecific antibody. This bispecific antibody (251xH22) mediates antibody–directed cellular cytotoxicity(ADCC) of AML cells mediated by normal leukocyte cells including natural killer cells, monocytes and granulocytes. They determined that there are direct signals transduced by binding of the anti-CD33 monoclonal antibody that lead to death of AML cells mediated in part by the protein kinase Syk. This led to an investigator-initiated multi-center Phase I/II clinical trial combining 5-azacytidine (that increases Syk expression) and the anti-CD33 monoclonal antibody Mylotarg. His laboratory has also been working the generation of cytotoxic T cells in vitro in a novel culture system. Based on this pre-clinical work, they developed a clinical trial wherein patients with AML undergoing autologous stem cell transplantation are administered autologous cytotoxic T cells following the transplant with the goal of reducing the relapse rate. Dr. Ball is principal investigator on numerous clinical trials active at UCSD Medical Center ranging from Phase I investigator-initiated to Phase III trials. He has been a recipient of a NCI and NHLBI-sponsored UO1 grant from the NIH. He recently completed a study of a novel treatment of relapse following allogeneic stem cell transplantation. The infusion of a monoclonal antibody directed to the cytotoxic T lymphocyte antigen-4 (CTLA-4) was tested in series of patients with relapse for safety and efficacy. The study demonstrated the safety of this approach and some promising signs of efficacy. Dr. Ball has been the elected Secretary of the American Society of Blood and Marrow Transplantation and a member of the steering committee of the BMT Clinical Trials Network.

    Education and Training
    BS - Biochemistry, University of Maryland - 1968-1972
    MD - Case Western Reserve University - 1972-1976
    Resident - Hartford Hospital - 1976-1979
    Fellow - Hematology & Oncolog, University Hospitals of Cleveland - 1979-1981
    Fellow - Hematology & Oncology, Dartmouth- Hitchcock Medical Center - 1982-1983


    Collapse Research 
    Collapse Research Activities and Funding
    Adoptive T-Cell Therapy for Acute Leukemia
    NIH/NCI R21CA132277Jan 1, 2010 - Dec 31, 2012
    Role: Principal Investigator
    Symposium- Advances in Stem Cell Transplantation
    NIH/NCI R13CA102080May 2, 2003 - Apr 30, 2004
    Role: Principal Investigator
    CTLA-4 Blockade in Allo Stem Cell Transplantation
    NIH/NCI R01CA093891Sep 30, 2002 - Aug 31, 2008
    Role: Principal Investigator
    CTLA-4 Blockade to Stimulate Allogeneic Graft vs Tumor
    NIH/NHLBI U01HL069273Sep 30, 2001 - Jul 31, 2013
    Role: Principal Investigator
    TARGETED CELLULAR TOXICITY OF SCCL CELLS
    NIH/NCI R03CA072657Sep 30, 1997 - Aug 31, 2000
    Role: Principal Investigator
    MONOCLONAL ANTIBODIES/SMALL CELL CARCINOMA OF THE LUNG
    NIH/NCI R01CA037868Sep 30, 1985 - May 31, 1995
    Role: Principal Investigator
    Monoclonal Antibody for Treatment of Leukemia
    NIH/NCI R01CA031888Jun 1, 1983 - Jun 30, 2006
    Role: Principal Investigator
    MONOCLONAL ANTIBODIES REACTIVE WITH HUMAN LEUKEMIA CELLS
    NIH/NCI R23CA031888Jun 1, 1983 - May 31, 1986
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Medeiros BC, Tanaka TN, Balaian L, Bashey A, Guzdar A, Li H, Messer K, Ball ED. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2018 May; 18(5):346-352.e5. PMID: 29572158.
      View in: PubMed
    2. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Br J Haematol. 2017 Aug 02. PMID: 28771676.
      View in: PubMed
    3. Balakrishnan A, Gloude N, Sasik R, Ball ED, Morris GP. Proinflammatory Dual Receptor T Cells in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1852-1860. PMID: 28750779.
      View in: PubMed
    4. Goodman A, Ball ED. What are the latest advancements in acute myeloid leukemia therapy? Future Oncol. 2017 Apr; 13(10):867-871. PMID: 28266249.
      View in: PubMed
    5. Goodman AM, Rust M, Costello C, Ball ED. A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis. Oncology (Williston Park). 2017 02 15; 31(2):122-4, 126-8. PMID: 28205192.
      View in: PubMed
    6. Chen YB, Efebera YA, Johnston L, Ball ED, Avigan D, Lekakis LJ, Bachier CR, Martin P, Duramad O, Ishii Y, Han S, Jung YJ, Lee D, Kunkel L, Negrin RS, Bui JD. Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant. 2017 Apr; 23(4):625-634. PMID: 28104514.
      View in: PubMed
    7. Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, Oehler VG, Broome EH, Ball ED, van der Horst EH, Ginsberg MH, Reya T. CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. Cancer Cell. 2016 Nov 14; 30(5):792-805. PMID: 27908736.
      View in: PubMed
    8. Crews LA, Balaian L, Delos Santos NP, Leu HS, Court AC, Lazzari E, Sadarangani A, Zipeto MA, La Clair JJ, Villa R, Kulidjian A, Storb R, Morris SR, Ball ED, Burkart MD, Jamieson CHM. RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. Cell Stem Cell. 2016 11 03; 19(5):599-612. PMID: 27570067.
      View in: PubMed
    9. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53. PMID: 27410923.
      View in: PubMed
    10. Wang HY, McMahon C, Ali SM, Young LE, Yekezare S, Ross JS, Ball ED. Novel FNDC3B and MECOM fusion and WT1 L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia. Br J Haematol. 2016 Mar; 172(6):987-90. PMID: 26147192.
      View in: PubMed
    11. Ong E, Szedlak A, Kang Y, Smith P, Smith N, McBride M, Finlay D, Vuori K, Mason J, Ball ED, Piermarocchi C, Paternostro G. A scalable method for molecular network reconstruction identifies properties of targets and mutations in acute myeloid leukemia. J Comput Biol. 2015 Apr; 22(4):266-88. PMID: 25844667; PMCID: PMC4394180.
    12. Zhong R, Li H, Messer K, Lane TA, Zhou J, Ball ED. Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists. Cancer Immunol Immunother. 2015 Jun; 64(6):737-44. PMID: 25795133; PMCID: PMC4742236.
    13. Cunard R, Marquez II, Ball ED, Nelson CL, Corringham S, Clopton P, Sanchez AP, Lane T, Ward DM. Prophylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants. Transfusion. 2014 Jul; 54(7):1857-63. PMID: 24372185.
      View in: PubMed
    14. Johnson RL, Boisot S, Ball ED, Wang HY. A case of interdigitating dendritic cell sarcoma/histiocytic sarcoma--a diagnostic pitfall. Int J Clin Exp Pathol. 2014; 7(1):378-85. PMID: 24427360; PMCID: PMC3885494.
    15. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013 Nov 20; 31(33):4199-206. PMID: 24127452; PMCID: PMC4878008.
    16. Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball ED, Kamble R, Avigan D, Maziarz RT, Ho VT, Koreth J, Alyea E, Soiffer R, Wingard JR, Boussiotis V, Spitzer TR, Antin JH. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8. PMID: 22766223; PMCID: PMC3496817.
    17. Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma. Pharmacotherapy. 2012 Jul; 32(7):596-603. PMID: 22760691.
      View in: PubMed
    18. Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. J Med Chem. 2012 Jan 26; 55(2):725-34. PMID: 22221201.
      View in: PubMed
    19. Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012 Feb; 18(2):280-8. PMID: 21810400; PMCID: PMC3224672.
    20. Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED. Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012 Feb; 18(2):257-64. PMID: 21736867.
      View in: PubMed
    21. Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15; 118(2):418-27. PMID: 21717444; PMCID: PMC4977021.
    22. Dimsdale JE, Ball ED, Carrier E, Wallace M, Holman P, Mulroney C, Shaikh F, Natarajan L. Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies. Support Care Cancer. 2011 Dec; 19(12):2015-20. PMID: 21116652; PMCID: PMC3204044.
    23. Zhou J, Bashey A, Zhong R, Corringham S, Messer K, Pu M, Ma W, Chut T, Soiffer R, Mitrovich RC, Lowy I, Ball ED. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant. 2011 May; 17(5):682-92. PMID: 20713164; PMCID: PMC2992836.
    24. Ball ED, Broome HE. Monoclonal antibodies in the treatment of hematologic malignancy. Best Pract Res Clin Haematol. 2010 Sep; 23(3):403-16. PMID: 21112039.
      View in: PubMed
    25. Espinosa-Aguilar L, Green JS, Forrest GN, Ball ED, Maziarz RT, Strasfeld L, Taplitz RA. Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences. Biol Blood Marrow Transplant. 2011 Apr; 17(4):566-73. PMID: 20708084.
      View in: PubMed
    26. Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). Biol Blood Marrow Transplant. 2011 Apr; 17(4):558-65. PMID: 20674758; PMCID: PMC3807877.
    27. Messer K, Natarajan L, Ball ED, Lane TA. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials. Stat Med. 2010 Mar 30; 29(7-8):712-20. PMID: 20213706.
      View in: PubMed
    28. Ball ED. Increasing the punch of reduced-intensity transplants. Blood. 2009 Dec 24; 114(27):5410-1. PMID: 20035041.
      View in: PubMed
    29. Trivedi M, Martinez S, Corringham S, Medley K, Ball ED. Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD. J Oncol Pharm Pract. 2011 Jun; 17(2):85-90. PMID: 20015929.
      View in: PubMed
    30. Jung AS, Holman PR, Castro JE, Carrier EK, Bashey A, Lane TA, Nelson CL, Pu M, Messer K, Corringham SM, Ball ED. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009 Oct; 15(10):1306-13. PMID: 19747639.
      View in: PubMed
    31. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 Feb 12; 113(7):1581-8. PMID: 18974373; PMCID: PMC2644086.
    32. Zhong RK, Lane TA, Ball ED. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells. Exp Hematol. 2008 Apr; 36(4):486-94. PMID: 18249062.
      View in: PubMed
    33. Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A, Carrier E, Castro JE, Holman PR, Xu R, Law P, Ball ED, Lane TA. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion. 2007 Nov; 47(11):2153-60. PMID: 17958545.
      View in: PubMed
    34. Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E, Maciejewski JP. Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol. 2007 Jan; 136(2):237-48. PMID: 17156396.
      View in: PubMed
    35. Nguyen DH, Ball ED, Varki A. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. Exp Hematol. 2006 Jun; 34(6):728-35. PMID: 16728277.
      View in: PubMed
    36. Zhou J, Chen J, Zhong R, Mokotoff M, Shultz LD, Ball ED. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2224-31. PMID: 16609038.
      View in: PubMed
    37. Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, Carrier E, Castro JE, Holman P, Lane TA, Hassidim K, Ball ED. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. Leuk Res. 2006 Apr; 30(4):503-6. PMID: 16303178.
      View in: PubMed
    38. Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol. 2005 Feb; 33(2):199-211. PMID: 15676214.
      View in: PubMed
    39. Zhou J, Chen J, Mokotoff M, Ball ED. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs. 2004 Nov; 15(10):921-7. PMID: 15514561.
      View in: PubMed
    40. Ball ED, Ho AD. Summary of the 12th international symposium on recent advances in stem cell transplantation. Exp Hematol. 2004 Oct; 32(10):881-4. PMID: 15504542.
      View in: PubMed
    41. Balaian L, Ball ED. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies. Leuk Res. 2004 Aug; 28(8):821-9. PMID: 15203280.
      View in: PubMed
    42. Zhong R, Law P, Wong D, Merzouk A, Salari H, Ball ED. Small peptide analogs to stromal derived factor-1 enhance chemotactic migration of human and mouse hematopoietic cells. Exp Hematol. 2004 May; 32(5):470-5. PMID: 15145215.
      View in: PubMed
    43. Ball ED. Update in hematology. Ann Intern Med. 2003 Dec 02; 139(11):916-22. PMID: 14644894.
      View in: PubMed
    44. Zhou J, Chen J, Mokotoff M, Zhong R, Shultz LD, Ball ED. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4953-60. PMID: 14581370.
      View in: PubMed
    45. Balaian L, Zhong RK, Ball ED. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol. 2003 May; 31(5):363-71. PMID: 12763134.
      View in: PubMed
    46. Castro JE, Ball ED. Development of allogeneic hematopoietic stem cell transplantation (HSCT). Cancer Treat Res. 2002; 110:1-37. PMID: 11908193.
      View in: PubMed
    47. Zhong RK, Rassenti LZ, Kipps TJ, Chen J, Law P, Yu JF, Ball ED. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. Biol Blood Marrow Transplant. 2002; 8(10):557-68. PMID: 12434951.
      View in: PubMed
    48. Ricordi C, Tzakis AG, Demetris AJ, Zeevi A, Rybka WB, Nalesnik MA, Ukah FO, Fontes PA, Ball ED, Starzl TE. Reversal of Graft-Versus-Host Disease with Infusion of Stored Autologous Bone Marrow Cells Following Combined Liver-Bone Marrow Allotransplantation in Man. Transplant Sci. 1993 Apr; 3(1):76-77. PMID: 21572946.
      View in: PubMed